常山药业股价涨5.48%，国泰基金旗下1只基金重仓，持有4.51万股浮盈赚取13.26万元

Group 1 - The core point of the news is that Changshan Pharmaceutical experienced a stock price increase of 5.48%, reaching 56.56 CNY per share, with a trading volume of 1.093 billion CNY and a turnover rate of 2.18%, resulting in a total market capitalization of 51.982 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, specializes in the research, production, and sales of heparin series products, with its main business revenue composition being 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [1] Group 2 - From the perspective of major fund holdings, data shows that Guotai Fund has a significant position in Changshan Pharmaceutical, with the Guotai ChiNext Medical and Health ETF (159377) increasing its holdings by 19,500 shares in the third quarter, totaling 45,100 shares, which accounts for 4.75% of the fund's net value, ranking as the fifth-largest holding [2] - The Guotai ChiNext Medical and Health ETF (159377) was established on April 2, 2025, with a latest scale of 43.2788 million CNY and a cumulative return of 21.59% since inception [2]